162 related articles for article (PubMed ID: 7497599)
1. Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma.
Toko T; Shibata J; Sugimoto Y; Yamaya H; Yoshida M; Ogawa K; Matsushima E
Cancer Chemother Pharmacol; 1995; 37(1-2):7-13. PubMed ID: 7497599
[TBL] [Abstract][Full Text] [Related]
2. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors.
Toko T; Sugimoto Y; Matsuo K; Yamasaki R; Takeda S; Wierzba K; Asao T; Yamada Y
Eur J Cancer; 1990 Mar; 26(3):397-404. PubMed ID: 2141500
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
Kawamura I; Mizota T; Kondo N; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1991 Oct; 57(2):215-24. PubMed ID: 1812300
[TBL] [Abstract][Full Text] [Related]
4. Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.
Wei LL; Mangel WF; Katzenellenbogen BS
J Steroid Biochem; 1985 Dec; 23(6A):875-81. PubMed ID: 3937947
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen.
Löser R; Seibel K; Roos W; Eppenberger U
Eur J Cancer Clin Oncol; 1985 Aug; 21(8):985-90. PubMed ID: 4043181
[TBL] [Abstract][Full Text] [Related]
6. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
Toko T; Shibata J; Nukatsuka M; Yamada Y
Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952
[TBL] [Abstract][Full Text] [Related]
7. Interaction of DP-TAT-59, an active metabolite of new triphenylethylene-derivative (TAT-59), with estrogen receptors.
Toko T; Matsuo K; Shibata J; Wierzba K; Nukatsuka M; Takeda S; Yamada Y; Asao T; Hirose T; Sato B
J Steroid Biochem Mol Biol; 1992 Nov; 43(6):507-14. PubMed ID: 1419885
[TBL] [Abstract][Full Text] [Related]
8. Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59).
Shibata J; Toko T; Saito H; Lykkesfeldt AE; Fujioka A; Sato K; Hashimoto A; Wierzba K; Yamada Y
Cancer Chemother Pharmacol; 2000; 45(2):133-41. PubMed ID: 10663628
[TBL] [Abstract][Full Text] [Related]
9. Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
Hilakivi-Clarke L; Wärri A; Bouker KB; Zhang X; Cook KL; Jin L; Zwart A; Nguyen N; Hu R; Cruz MI; de Assis S; Wang X; Xuan J; Wang Y; Wehrenberg B; Clarke R
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27609189
[TBL] [Abstract][Full Text] [Related]
10. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat.
di Salle E; Zaccheo T; Ornati G
J Steroid Biochem; 1990 Jun; 36(3):203-6. PubMed ID: 2142233
[TBL] [Abstract][Full Text] [Related]
11. The measurement of tamoxifen and metabolites in the rat and relationship to the response of DMBA-induced mammary tumours.
Daniel CP; Gaskell SJ; Nicholson RI
Eur J Cancer Clin Oncol; 1984 Jan; 20(1):137-43. PubMed ID: 6420159
[TBL] [Abstract][Full Text] [Related]
12. [Effect of tamoxifen plus octreotide on DMBA-induced mammary tumors in rats].
Zeng XZ; Yao ZX
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):28-32. PubMed ID: 15808071
[TBL] [Abstract][Full Text] [Related]
13. PSK (krestin) potentiates chemotherapeutic effects of tamoxifen on rat mammary carcinomas.
Iino Y; Takai Y; Sugamata N; Morishita Y
Anticancer Res; 1992; 12(6B):2101-3. PubMed ID: 1295453
[TBL] [Abstract][Full Text] [Related]
14. Prevention of DMBA-induced rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen.
Hollingsworth AB; Lerner MR; Lightfoot SA; Wilkerson KB; Hanas JS; McCay PB; Brackett DJ
Breast Cancer Res Treat; 1998 Jan; 47(1):63-70. PubMed ID: 9493977
[TBL] [Abstract][Full Text] [Related]
15. A new triphenylethylene derivative, TAT-59; hormone receptors; insulin-like growth factor 1; and growth suppression of hormone-dependent MCF-7 tumors in athymic mice.
Iino Y; Takai Y; Ando T; Ohwada S; Yokoe T; Sugamata N; Takei H; Horiguchi J; Iijima K; Morishita Y
Cancer Chemother Pharmacol; 1994; 34(5):372-6. PubMed ID: 8070003
[TBL] [Abstract][Full Text] [Related]
16. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
[TBL] [Abstract][Full Text] [Related]
17. Binding sites of droloxifene in the cytosol of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.
Kawamura I; Lacey E; Tanaka Y; Nishigaki F; Manda T; Shimomura K
Jpn J Cancer Res; 1994 Jun; 85(6):639-44. PubMed ID: 8063618
[TBL] [Abstract][Full Text] [Related]
18. Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model.
De Oliveira Andrade F; Yu W; Zhang X; Carney E; Hu R; Clarke R; FitzGerald K; Hilakivi-Clarke L
Endocr Relat Cancer; 2019 Mar; 26(3):339-353. PubMed ID: 30640711
[TBL] [Abstract][Full Text] [Related]
19. Effect of tamoxifen on intraperitoneal N-nitroso-N-methylurea induced tumors.
Martin G; Melito G; Rivera E; Levin E; Davio C; Cricco G; Andrade N; Caro R; Bergoc R
Cancer Lett; 1996 Feb; 100(1-2):227-34. PubMed ID: 8620446
[TBL] [Abstract][Full Text] [Related]
20. Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen.
Mansour A; Daba A; Baddour N; El-Saadani M; Aleem E
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1579-96. PubMed ID: 22552717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
